NASDAQ:CORTCorcept Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $15.14 -0.10 (-0.66 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$14.62Now: $15.14▼$15.3950-Day Range$11.00MA: $13.28▼$15.7552-Week Range$9.55Now: $15.14▼$17.48Volume1.07 million shsAverage Volume1.02 million shsMarket Capitalization$1.74 billionP/E Ratio17.20Dividend YieldN/ABeta1.1 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing's syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.67, Corcept Therapeutics has a potential upside of 16.7% from its current price of $15.14.Amount of Analyst CoverageCorcept Therapeutics has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesCorcept Therapeutics has received 467 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCorcept Therapeutics has received 391 “underperform” votes. (Add your “underperform” vote.)Community SentimentCorcept Therapeutics has received 54.43% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Corcept Therapeutics and other stocks. Vote “Outperform” if you believe CORT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CORT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $551,500.00 in company stock.Percentage Held by InsidersOnly 15.50% of the stock of Corcept Therapeutics is held by insiders.Percentage Held by Institutions76.15% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to decrease by -33.73% in the coming year, from $0.83 to $0.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 17.20, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 17.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.09.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 4.24. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CORT Previous Symbol CUSIP21835210 CIK1088856 Webwww.corcept.com Phone650-327-3270Debt Debt-to-Equity RatioN/A Current Ratio10.12 Quick Ratio9.97Price-To-Earnings Trailing P/E Ratio17.20 Forward P/E Ratio18.24 P/E GrowthN/A Sales & Book Value Annual Sales$306.49 million Price / Sales5.66 Cash Flow$0.85 per share Price / Cash Flow17.91 Book Value$3.57 per share Price / Book4.24Profitability EPS (Most Recent Fiscal Year)$0.77 Net Income$94.18 million Net Margins31.64% Return on Equity30.00% Return on Assets27.29%Miscellaneous Employees166 Outstanding Shares114,602,000Market Cap$1.74 billion Next Earnings Date8/6/2020 (Estimated) OptionableOptionable NASDAQ:CORT Rates by TradingView Receive CORT News and Ratings via Email Sign-up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Corcept Therapeutics (NASDAQ:CORT) Frequently Asked Questions How has Corcept Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Corcept Therapeutics' stock was trading at $10.95 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CORT shares have increased by 38.3% and is now trading at $15.14. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Corcept Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corcept Therapeutics. When is Corcept Therapeutics' next earnings date? Corcept Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Corcept Therapeutics. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) released its quarterly earnings results on Monday, May, 4th. The biotechnology company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.22 by $0.03. The biotechnology company had revenue of $93.25 million for the quarter, compared to analysts' expectations of $87.01 million. Corcept Therapeutics had a return on equity of 30.00% and a net margin of 31.64%. The business's revenue for the quarter was up 43.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.20 earnings per share. View Corcept Therapeutics' earnings history. What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics issued an update on its FY 2020 After-Hours earnings guidance on Monday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $355-375 million, compared to the consensus revenue estimate of $363.79 million. What price target have analysts set for CORT? 3 brokerages have issued twelve-month price objectives for Corcept Therapeutics' shares. Their forecasts range from $15.00 to $20.00. On average, they expect Corcept Therapeutics' share price to reach $17.67 in the next twelve months. This suggests a possible upside of 16.7% from the stock's current price. View analysts' price targets for Corcept Therapeutics. Has Corcept Therapeutics been receiving favorable news coverage? Headlines about CORT stock have trended very negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Corcept Therapeutics earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutCorcept Therapeutics. Are investors shorting Corcept Therapeutics? Corcept Therapeutics saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 21,980,000 shares, an increase of 5.5% from the April 15th total of 20,830,000 shares. Based on an average daily trading volume, of 1,120,000 shares, the short-interest ratio is presently 19.6 days. Approximately 21.3% of the shares of the stock are short sold. View Corcept Therapeutics' Current Options Chain. Who are some of Corcept Therapeutics' key competitors? Some companies that are related to Corcept Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Zogenix (ZGNX). View all competitors. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), CA (CA), Advanced Micro Devices (AMD), Alibaba Group (BABA), BlackRock (BLK), AbbVie (ABBV), Netflix (NFLX), Energy Transfer LP Unit (ET) and Johnson & Johnson (JNJ). Who are Corcept Therapeutics' key executives? Corcept Therapeutics' management team includes the following people: Dr. Joseph K. Belanoff, Co-Founder, Pres, CEO & Director (Age 62)Mr. Gary Charles Robb, CFO & Sec. (Age 56)Mr. Sean Maduck, Sr. VP of Commercial (Age 42)Dr. Christopher Shayne James M.D., Director of Investor RelationsDr. Hazel Hunt Ph.D., Sr. VP of Research What is Corcept Therapeutics' stock symbol? Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT." Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.30%), Ingalls & Snyder LLC (6.98%), Federated Hermes Inc. (4.55%), State Street Corp (2.77%), Geode Capital Management LLC (1.29%) and Invesco Ltd. (1.19%). Company insiders that own Corcept Therapeutics stock include Daniel N Swisher Jr, G Leonard Baker Jr, Gary Charles Robb, Joseph K Belanoff, Robert S Fishman and Sean Maduck. View institutional ownership trends for Corcept Therapeutics. Which institutional investors are selling Corcept Therapeutics stock? CORT stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., BlackRock Inc., Invesco Ltd., Morgan Stanley, Morgan Stanley, First Trust Advisors LP, Wellington Management Group LLP, and Engineers Gate Manager LP. Company insiders that have sold Corcept Therapeutics company stock in the last year include Daniel N Swisher Jr, and G Leonard Baker Jr. View insider buying and selling activity for Corcept Therapeutics. Which institutional investors are buying Corcept Therapeutics stock? CORT stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Matarin Capital Management LLC, AJO LP, MERIAN GLOBAL INVESTORS UK Ltd, Oxford Financial Group Ltd., Aviva PLC, Schroder Investment Management Group, and Nuveen Asset Management LLC. View insider buying and selling activity for Corcept Therapeutics. How do I buy shares of Corcept Therapeutics? Shares of CORT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Corcept Therapeutics' stock price today? One share of CORT stock can currently be purchased for approximately $15.14. How big of a company is Corcept Therapeutics? Corcept Therapeutics has a market capitalization of $1.74 billion and generates $306.49 million in revenue each year. The biotechnology company earns $94.18 million in net income (profit) each year or $0.77 on an earnings per share basis. Corcept Therapeutics employs 166 workers across the globe. What is Corcept Therapeutics' official website? The official website for Corcept Therapeutics is www.corcept.com. How can I contact Corcept Therapeutics? Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-327-3270 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
